Optimization data for determination of montelukast and bambuterol as a combined medication

Sensitive, simple and green analytical methodology for simultaneous
estimation of bambuterol and montelukast as a combined medication based on
their native fluorescence character was developed. The method relies on
synchronous spectrofluorimety to solve the problem of the overlapping
emission spectra of the studied drugs. Where, utilizing second derivative
synchronous spectra enabled the simultaneous quantitation of bambuterol
and montelukast without interference. The peak amplitudes of the aqueous
solutions at Δλ = 20 nm were estimated at 284 nm & 304 nm for
bambuterol and at 374 nm & 384 nm for montelukast. A linear
relationship was achieved over the concentration range of 0.2–1.00 μg/mL
for bambuterol and 0.4–2.00 μg/mL for montelukast. All factors and
parameters were carefully studied to obtain the highest sensitivity and
good precision of the proposed method. Additionally, the validation
criteria were assessed in accordance with ICH guidelines. The method was
utilized for the estimation of both drugs in their raw materials,
synthetic mixtures as well their combined tablets with good agreement
between its results and those from the comparison method.